Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 2
Abstract
The goal of treatment for chronic hepatitis C viral (HCV) infection is to cure the infection rather than suppress the virus. Historically, a sustained virological response (SVR) defined as undetectable HCV RNA at 24 weeks following the completion of treatment was considered the gold standard to define successful eradication of the virus as a primary endpoint in clinical trials. SVR measured at 12 weeks post-treatment has been shown to be highly concordant with SVR24 in trials of pegylated interferon and ribavirin. The appropriateness and durability of SVR12 as the efficacy endpoint with new oral direct-acting antivirals is less established. A literatura search was performed using PubMed, EMBASE and CENTRAL databases to identify any studies that examined the concordance between SVR24 and earlier time points. Two studies and 4 abstracts were found that performed concordance analyses using positive and negative predictive values. Overall, SVR4 and SVR12 were highly concordant with SVR24 with high positive (> 97%) and negative (> 94%) predictive values; however there was a higher risk of HCV relapse occurring after post-treatment week 4. The majority of the data focused on SVR12 and demonstrated that SVR12 reliably predicted SVR24 in several populations infected with HCV (treatment-naïve, prior null responders, different genotypes) using various new oral direct-acting antiviral regimens. In conclusion, the available data suggests that SVR12 is a reliable assessment of HCV eradication and could be used instead of SVR24 for drug development clinical trials assessing efficacy of new direct-acting antivirals. Data on the long-term durability of SVR12 is still needed.
Authors and Affiliations
Sarah V. Burgess, Trana Hussaini, Eric M. Yoshida
Keywords
Related Articles
- EP ID EP78551
- DOI -
- Views 104
- Downloads 0
Pegylated interferon, but not conventional interferon therapy induced severe skin lesions
Portal vein thrombosis in patients with cirrhosis: just a common finding or a predictor of poor outcome?
Background & Aims. It is unclear whether portal vein thrombosis (PVT) unrelated to malignancy is associated with reduced survival or it is an epiphenomenon of advanced cirrhosis. The objective of this study...
A Dynamic Model for Predicting Outcome in Patients with HBV Related Acute-On-Chronic Liver Failure
Introduction and aim. Accurately predicting the prognosis of individual patient is crucial in the management of ACLF. We aimed to establish a specific prognostic model for HBV-related ACLF patients treated with nucleosid...
Leptin in nonalcoholic fatty liver disease
Background: Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition associated with obesity and insulin resistance (IR). Leptin plays a key role in the control of energy balance, and insulin sensitivity. In th...
Noninvasive diagnosis of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, affecting approximately 30% of Western populations and a frequent indication for liver transplantation. The histologic spectrum...